The comparative efficacy and risk of harms of the intravenous and subcutaneous formulations of trastuzumab in patients with HER2-positive breast cancer: a rapid review

BACKGROUND: Trastuzumab is a monoclonal antibody for patients with HER2 (human epidermal growth factor receptor 2)-positive breast cancer, which is added to regular treatment and reduces mortality. Originally, trastuzumab had to be administered intravenously (IV) over 30 min every 3 weeks for 1 year...

Descripción completa

Detalles Bibliográficos
Autores principales: Van den Nest, Miriam, Glechner, Anna, Gold, Maria, Gartlehner, Gerald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6905114/
https://www.ncbi.nlm.nih.gov/pubmed/31829250
http://dx.doi.org/10.1186/s13643-019-1235-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6905114/
https://www.ncbi.nlm.nih.gov/pubmed/31829250
http://dx.doi.org/10.1186/s13643-019-1235-x

Ejemplares similares